Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - macrogol 4000 55 mg/ml - oral solution - 55 g/l - active: macrogol 4000 55 mg/ml excipient: soluble lemon essence potassium chloride saccharin sodium sodium bicarbonate sodium chloride sodium sulfate water for injection

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

biomed limited - macrogol 4000 60 g/l; potassium chloride 0.75 g/l; sodium bicarbonate 1.68 g/l; sodium chloride 1.46 g/l; sodium sulfate decahydrate 5.685 g/l - oral solution - 60 g/l - active: macrogol 4000 60 g/l potassium chloride 0.75 g/l sodium bicarbonate 1.68 g/l sodium chloride 1.46 g/l sodium sulfate decahydrate 5.685 g/l excipient: water for injection

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ipsen consumer healthcare - macrogol 64 g; sodium sulfate anhydrous 5,7 g; potassium chloride 0,75 g; sodium chloride 1,46 g; sodium hydrogen carbonate 1,68 g - powder for oral solution - macrogol 4000 64 g; potassium chloride 0.75 g; sodium bicarbonate 1.68 g; sodium sulfate 5.7 g; sodium chloride 1.46 g - macrogol, combinations

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ipsen consumer healthcare - macrogol 10 g - powder for oral solution - 10 g - macrogol 4000 10 g - macrogol

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ipsen consumer healthcare - macrogol 4 g - powder for oral solution - 4 g - macrogol 4000 4 g - macrogol

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

galen ltd - sodium; chloride; potassium; bicarbonate; macrogol '3350' - powder for oral solution - 65mmol/1litre ; 53mmol/1litre ; 5.4mmol/1litre ; 17mmol/1litre ; 105gram/1litre

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin, quantity: 500 mg; clavulanic acid, quantity: 125 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; dimeticone 5000; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organisms(s) and its (their) susceptibility to augmentin tablets. however, when there is reason to believe an infection may involve any of the b-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and b-lactamase producing organisms susceptible to augmentin tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg;  ; potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg   potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg   excipient: colloidal silicon dioxide dimeticone hypromellose macrogol 4000 macrogol 6000 magnesium stearate microcrystalline cellulose opadry white oy-s-7300 as an alternative source of film coat sodium starch glycolate titanium dioxide - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

am distributions (yorkshire) ltd - macrogol '3350'; sodium; chloride; bicarbonate; potassium - powder for oral solution - 105gram/1litre ; 65mmol/1litre ; 53mmol/1litre ; 17mmol/1litre ; 5.4mmol/1litre

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - macrogol '3350'; sodium; chloride; bicarbonate; potassium - powder for oral solution - 105gram/1litre ; 65mmol/1litre ; 53mmol/1litre ; 17mmol/1litre ; 5.4mmol/1litre